Article: Neurocrine Biosciences Announces Study Showing Indiplon Immediate Release Safe for Middle of the Night Dosing Without Next Day Residual Effects; Data Presented at the American Psychiatric Association (APA) Meeting.

Neurocrine Biosciences, Inc. announced results from a study in healthy volunteers presented today that shows that indiplon immediate release when taken in the middle of the night (MOTN) is safe and well tolerated without evidence of next day residual effects. These results were presented at the 157th annual meeting of the American Psychiatric Association (APA) in New York City.

"This is promising data for patients who have trouble staying asleep and wake up frequently in the middle of the night. They are often concerned that taking a sleep medication will leave them feeling groggy the next day," said Dr. Marty Scharf, Director, Tri-State Sleep Disorders Center ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!